

Our ref: FOI 1079

26th May 2022

SOUTHERN HEALTH & SOCIAL CARE TRUST

FREEDOM OF INFORMATION RESPONSE 1079

Part 1:

I have a freedom of information request regarding the use of Biologic medicines. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

• Adalimumab - Humira	26
• Adalimumab Biosimilar	187
• Apremilast	0
• Bimekizumab	0
• Brodalumab	10
• Certolizumab	<5
• Dimethyl fumarate	0
• Etanercept - Enbrel	0
• Etanercept Biosimilar	<5
• Guselkumab	61
• Infliximab - Remicade	0
• Infliximab Biosimilar	6
• Ixekizumab	33
• Risankizumab	28

• Secukinumab	33
• Tildrakizumab	13
• Ustekinumab	34

Part 2:

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab

• Adalimumab - Humira	8
• Adalimumab Biosimilar	175
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	<5
• Infliximab Biosimilar	80
• Ozanimod	0
• Tofacitinib	6
• Ustekinumab	82
• Vedolizumab	84

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals

concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net